Betamethasone butyrate propionate (BBP) was introduced in Japan as a
topical antiinflammatory agent. It is a synthetic corticosteroid with strong
antiinflammatory activity at the site of inflammation but without topical or systemic
side effects. On paper disk granuloma in rats, BBP was shown to have higher
degree of dissociation between antiinflammation efficacy and systemic side effects
than other agents in this class. Antipyretic/analgesic properties have also been
reported.
Betamethasone-17-butyrate-21-propionate are used in the treatment of vitiligo vulgaris with the combination therapy of topical steroid and vitamin D3 compound.
ChEBI: Betamethasone butyrate propionate is a corticosteroid hormone.
